Crenolanib combination therapy
The present invention includes methods for treating a proliferative disorder by blocking both PDGFR and VEGFR signaling comprising a therapeutically effective amount of crenolanib or salt in combination with a VEGF/VEGFR inhibitor that is not axitinib wherein the crenolanib, VEGF/VEGFR inhibitor that is not axitinib are provided at least one of sequentially or concomitantly, in a subject for use in the treatment of the proliferative disorder, wherein the subject is a human subject.
1. A method for treating a proliferative disorder comprising administering to a subject a therapeutically effective amount of crenolanib or salt thereof in combination with a vascular endothelial growth factor (VEGF), a vascular endothelial growth factor receptor (VEGFR), or both (VEGF/VEGFR) inhibitor that is not axitinib sufficient to treat the proliferative disorder.
2. The method of claim 1 , wherein the proliferative disorder is at least one of: biliary tract cancer, bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, colorectal carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, gastric adenocarcinoma, stage IIIB gastric adenocarcinoma, stage IV invasive gastric adenocarcinoma, metastatic esophageal adenocarcinoma, glioblastoma, head and neck cancer, hepatocellular carcinoma, liver cancer, lung cancer, melanoma, non-small cell cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell cancer lung cancer, squamous cell cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, thymoma, uterine cancer, or other tumors.
3. The method of claim 1 , wherein the therapeutically effective amount of crenolanib or a salt thereof is from about 50 mg to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day 350 to 500 mg per day, or 400 to 500 mg per day.
4. The method of claim 1 , wherein the therapeutically effective amount of crenolanib or salt thereof, the VEGF/VEGFR inhibitor, or both, is administered at least one of continuously, intermittently, systemically, or locally.
5. The method of claim 1 , wherein the therapeutically effective amount of crenolanib or salt thereof, the VEGF/VEGFR inhibitor, or both, is administered orally, intravenously, or intraperitoneally.
6. The method of claim 1 , wherein crenolanib is crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib toluenesulfonate, and crenolanib succinate.
7. The method of claim 1 , further comprising providing the subject a chemotherapeutic agent that comprises one or more of alkylating agents, antimetabolites, natural products, or a combination thereof.
8. The method of claim 7 , wherein the chemotherapeutic agent is provided in a therapeutically effective amount and is selected from:
an alkylating agent that comprises one or more of carmustine, chlorambucil, cyclophosphamide, ifosfamide, lomustine, streptozotocin, temozolomide, cisplatin, carboplatin, nedaplatin, or oxaliplatin;
an anti-proliferative agent that comprises one or more of vinblastine, vinorelbine, vincristine, vindesine, vinflunine, paclitaxel, docetaxel, cabazitaxel, etoposide, teniposide, topotecan, irinotecan, doxorubicin, epirubicin, valrubicin, mitoxantrone, bleomycin, estramustine, or mitomycin; or
an antimetabolite that comprises one or more of methotrexate, pemetrexed, raltitrexed, fluorouracil, floxuridine, capcitabine, or gemcitabine.
9. The method of claim 8 , wherein a therapeutically effective amount of the alkylating agent is from about 22 mg to 40 mg every 6 weeks, 150 to 200 mg every 6 weeks, 4 to 20 mg per day for 3 to 6 weeks, 2,000 to 4,750 given over 5 days, 4 to 19 mg per day, 1.44 to 3.12 g per day for 5 days in 3 weeks, 150 to 340 mg every 6 weeks, 600 to 1,300 mg per day for 5 days within 6 weeks, 90 to 390 mg daily, 24 to 260 mg per day for 5 days within 6 weeks, 240 to 1,690 mg every 6 weeks, 72 to 234 mg every 4 weeks 78 to 221 mg every 2 weeks.
10. The method of claim 8 , wherein a therapeutically effective amount of the antimetabolite is from about 3.6 to 7.8 mg, 12 to 1,300 mg, 600 to 1,300 mg on day 1 of 21-day cycles.
11. The method of claim 8 , wherein the therapeutically effective amount of the chemotherapeutic agent is administered at least one of continuously, intermittently, systemically, or locally.
12. The method of claim 8 , wherein the therapeutically effective amount of the chemotherapeutic agent is from about 0.48 mg to 3.7 mg, 7.2 mg to 28.9 mg, 30 mg to 78 mg, 96 mg to 455 mg, 72 mg to 260 mg, 400 mg to 760 mg every three weeks; 42 to 260 mg given days 1, 3, 5 of 21 day cycle, 198 mg to 650 mg once weekly, 0.9 mg to 3.9 mg daily for 5 days of 21 day cycle, 150 mg to 910 mg daily for 5 days of 21 day cycle, 48 mg to 195 mg every 21 days, 90 mg to 312 mg once every 3 or 4 weeks, 800 mg once weekly every 6 weeks, 14.4 mg to 36.4 mg every 21 days, 12.5 units to 47.5 units every 1 to 2 weeks, 500 mg to 1,520 mg per day, 12 mg to 52 mg every 6 to 8 weeks.
13. The method of claim 1 , wherein the VEGF/VEGFR inhibitor that is not axitinib is selected from at least one of: ramucirumab, bevacizumab, ranibizumab, aflibercept, HLX12, ziv-aflibercept, vanucizumab, TX16, UB-922, BEVZ92, BCD-021, BI695502, CHS-5217, JHL1149, FKB238, Abevmy, ONS1045, PF06439535, HD204, SB8, TAB008, RPH001, BP102, HLX04, CT-P16, IBI305, LY01008, Mvasi, apagen, CHS-3351, PF582, Xlucane, FYB201, razumab, CHS-2020, FYB203, ABP-201, sevacizumab, brolucizumab, CSL346, faricimab, hPV19, TAB014, UB-924, VGX-100, VX70, STI-A0168, CVX-241, BI 836880, ABT-165, conbercept, MP0250, MP0260, angiocal, abicipar pegol, anlotinib, apatinib, altiratinib, vandetanib, linifanib, motesanib, necuparanib, HLX12, APX004, CDP791, HLX-06, IBI302, icrucumab, IMC-1C11, IMC-3C5, MSB0254, navicixizumab, tanibirumab, V-DOS47, cabozantinib, brivanib, dovitinib lactate, famitinib, foretinib, fruquintinib, golvatinib, henatinib, ponatinib, lenvatinib, lucitanib, sorafenib, nintedanib, orantinib, pegdinetanib, cediranib, rivoceranib, midostaurin, sitravatinib, regorafenib, sunitinib, sulfatinib, tesevatinib, tivozanib, vatalanib, or pazopanib.
14. The method of claim 1 , wherein the therapeutically effective amount of the VEGF/VEGFR inhibitor that is not axitinib is from about 250 mg to 1,425 mg every two to three weeks, 400 mg to 2,600 mg every two to three weeks, 40 mg to 475 mg every two weeks.
15. The method of claim 1 , wherein the therapeutically effective amount of crenolanib, VEGF/VEGFR inhibitor that is not axitinib and a pharmaceutical agent, are administered from at least one of:
for as long as the subject needs treatment for the proliferative disorder;
one or more times a day or more for as long as the subject is in need of treatment for the proliferative disorder;
for a patient with a newly diagnosed proliferative disorder or the proliferative disorder has progressed on at least one line of chemotherapy in the advanced setting; or
up to three times a day for as long as the subject is in need of treatment of the proliferative disorder.
16. A method for dual inhibition of angiogenesis by inhibition of both PDGFR and VEGFR signaling as a treatment of a proliferative disorder in a subject comprising a composition comprising a therapeutically effective amount of a VEGF/VEGFR inhibitor that is not axitinib, and a therapeutically effective amount of crenolanib or pharmaceutically acceptable salt thereof, wherein the subject is a human subject.
17. The method of claim 16 , wherein the proliferative disorder is at least one of: biliary tract cancer, bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, colorectal carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, gastric adenocarcinoma, stage IIIB gastric adenocarcinoma, stage IV invasive gastric adenocarcinoma, metastatic esophageal adenocarcinoma, glioblastoma, head and neck cancer, hepatocellular carcinoma, liver cancer, lung cancer, melanoma, non-small cell cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell cancer lung cancer, squamous cell cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, thymoma, uterine cancer, or other tumors.
18. The method of claim 16 , wherein the therapeutically effective amount of crenolanib or a salt thereof is from about 50 mg to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day 350 to 500 mg per day, or 400 to 500 mg per day.
19. The method of claim 16 , further comprising a pharmaceutical agent comprises one or more of paclitaxel, docetaxel, 5-fluorouracil, irinotecan, leucovorin calcium, oxaliplatin, capecitabine, interferon alpha, temozolomide, carboplatin, pegylated liposomal doxorubicin, topotecan, cisplatin, pemetrexed or a combination thereof.
20. The method of claim 16 , wherein the VEGF/VEGFR inhibitor that is not axitinib comprises ramucirumab, bevacizumab, ranibizumab, aflibercept, HLX12, ziv-aflibercept, vanucizumab, TX16, UB-922, BEVZ92, BCD-021, BI695502, CHS-5217, JHL1149, FKB238, Abevmy, ONS1045, PF06439535, HD204, SB8, TAB008, RPH001, BP102, HLX04, CT-P16, IBI305, LY01008, Mvasi, apagen, CHS-3351, PF582, Xlucane, FYB201, razumab, CHS-2020, FYB203, ABP-201, sevacizumab, brolucizumab, CSL346, faricimab, hPV19, TAB014, UB-924, VGX-100, VX70, STI-A0168, CVX-241, BI 836880, ABT-165, conbercept, MP0250, MP0260, angiocal, abicipar pegol, anlotinib, apatinib, altiratinib, vandetanib, linifanib, motesanib, necuparanib, HLX12, APX004, CDP791, HLX-06, IBI302, icrucumab, IMC-1C11, IMC-3C5, MSB0254, navicixizumab, tanibirumab, V-DOS47, cabozantib, brivanib, dovitinib lactate, famitinib, foretinib, fruquintinib, golvatinib, henatinib, ponatinib, lenvatinib, lucitanib, sorafenib, nintedanib, orantinib, pegdinetanib, cediranib, rivoceranib, midostaurin, sitravatinib, regorafenib, sunitinib, sulfatnib, tesevatinib, tivozanib, valatanib, or pazopanib.
21. The method of claim 16 , wherein the VEGF/VEGFR inhibitor that is not axitinib therapeutically effective amount is from about 250 mg to 1,425 mg every two to three weeks, 400 mg to 2,600 mg every two to three weeks, 40 mg to 475 mg every two weeks.
22. The method of claim 16 , wherein the therapeutically effective amount of the crenolanib or a salt thereof, the VEGF/VEGFR inhibitor that is not axitinib, or both, is at least one of:
administered at least one of continuously, intermittently, systemically, or locally; administered in an amount to keep the subject in a state of stable disease, or to cause a partial response, or complete response for as long as the subject needs such treatment for the proliferative disorder; or
administered up to three times a day for as long as the subject is in need for the treatment of the proliferative disorder.
23. The method of claim 16 , wherein crenolanib is crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib toluenesulfonate, or crenolanib succinate.
24. The method of claim 16 , wherein the therapeutically effective amount of the composition is administered orally, intravenously, subcutaneously, or intraperitoneally.
25. The method of claim 16 , further comprising the step of determining if the proliferative disorder is resistant to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy.
26. A pharmaceutical composition for treatment of a cancer in a human subject comprising: a crenolanib or salt thereof and a VEGF/VEGFR inhibitor that is not axitinib in a therapeutically effective amount for the treatment of the cancer.
27. The pharmaceutical composition of claim 26 , wherein the cancer is at least one of: biliary tract cancer, bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, colorectal carcinoma, esophageal cancer, gastric cancer, gastroesophageal junction (GEJ) adenocarcinoma, gastric adenocarcinoma, stage IIIB gastric adenocarcinoma, stage IV invasive gastric adenocarcinoma, metastatic esophageal adenocarcinoma, glioblastoma, head and neck cancer, hepatocellular carcinoma, liver cancer, lung cancer, melanoma, non-small cell cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell cancer lung cancer, squamous cell cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, thymoma, uterine cancer, or other solid tumors.
28. The pharmaceutical composition of claim 26 , wherein the crenolanib is formulated for dosing at 50 mg to 500 mg per day, 100 to 450 mg per day, 200 to 400 mg per day, 300 to 500 mg per day 350 to 500 mg per day, or 400 to 500 mg per day.
29. The pharmaceutical composition of claim 26 , wherein the crenolanib is formulated to be administered continuously, intermittently, systemically, or locally.
30. The pharmaceutical composition of claim 26 , wherein a therapeutically effective amount of crenolanib, VEGF/VEGFR inhibitor that is not axitinib, or both, is formulated to be administered orally, intravenously, or intraperitoneally.
31. The pharmaceutical composition of claim 26 , wherein crenolanib is crenolanib besylate, crenolanib phosphate, crenolanib lactate, crenolanib hydrochloride, crenolanib citrate, crenolanib acetate, crenolanib toluenesulfonate, and crenolanib succinate.
32. The pharmaceutical composition of claim 26 , further comprising a chemotherapeutic agent in an amount effective to treat the cancer, wherein the chemotherapeutic agent is selected from at least one of: one or more alkylating agents, one or more antimetabolites, one or more anti-proliferative agents, or a combination thereof.
33. The pharmaceutical composition of claim 32 , wherein the chemotherapeutic agent is at least one of:
an alkylating agent that comprises one or more of carmustine, chlorambucil, cyclophosphamide, ifosfamide, lomustine, streptozotocin, temozolomide, cisplatin, carboplatin, nedaplatin, or oxaliplatin;
antimetabolite that comprises one or more of methotrexate, pemetrexed, raltitrexed, fluorouracil, floxuridine, capecitabine, or gemcitabine; or
anti-proliferative agents that comprise one or more of vinblastine, vinorelbine, vincristine, vindesine, vinflunine, paclitaxel, docetaxel, cabazitaxel, etoposide, teniposide, topotecan, irinotecan, doxorubicin, epirubicin, valrubicin, mitoxantrone, bleomycin, estramustine, or mitomycin.
34. The pharmaceutical composition of claim 26 , wherein the VEGF/VEGFR inhibitor that is not axitinib comprises ramucirumab, bevacizumab, ranibizumab, aflibercept, HLX12, ziv-aflibercept, vanucizumab, TX16, UB-922, BEVZ92, BCD-021, BI695502, CHS-5217, JHL1149, FKB238, Abevmy, ONS1045, PF06439535, HD204, SB8, TAB008, RPH001, BP102, HLX04, CT-P16, IBI305, LY01008, Mvasi, apagen, CHS-3351, PF582, Xlucane, FYB201, razumab, CHS-2020, FYB203, ABP-201, sevacizumab, brolucizumab, CSL346, faricimab, hPV19, TAB014, UB-924, VGX-100, VX70, STI-A0168, CVX-241, BI 836880, ABT-165, conbercept, MP0250, MP0260, angiocal, abicipar pegol, anlotinib, apatinib, altiratinib, vandetanib, linifanib, motesanib, necuparanib, HLX12, APX004, CDP791, HLX-06, IBI302, icrucumab, IMC-1C11, IMC-3C5, MSB0254, navicixizumab, tanibirumab, V-DOS47, cabozantib, brivanib, dovitinib lactate, famitinib, foretinib, fruquintinib, golvatinib, henatinib, ponatinib, lenvatinib, lucitanib, sorafenib, nintedanib, orantinib, pegdinetanib, cediranib, rivoceranib, midostaurin, sitravatinib, regorafenib, sunitinib, sulfatnib, tesevatinib, tivozanib, valatanib, or pazopanib.